References
- Acocella G. Clinical pharmacokinetics of rifampicin. Clinical Pharmacokinetics 1978; 3: 108–127
- Acocella G., Pagani V., Marchetti M., Baroni G. C., Nicolis F. B. Kinetic studies on rifampicin. Chemotherapy 1971; 16: 356–370
- Biagi G. L., Barbaro A. M., Gamba M. F., Guerra M. C. Partition data of penicillins determined by means of reversed-phase thin-layer chromatography. Journal of Chromatography 1969; 41: 371–379
- Cocchiara G., Strolin Benedetti M., Vicario G. P., Ballabio M., Gioia B., Vioglio S., Vigevani A. Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers. Xenobiotica 1989; 19: 769–780
- Della Bruna C., Schioppacassi G., Ungheri D., Jabes D., Morvillo E., Sanfilippo A. LM 427, a new spiropiperidylrifamicin: ‘in vitro’ and ‘in vivo’ studies. Journal of Antibiotics 1983; 36: 1502–1506
- Loos U., Musch E., Jensen J. C., Mikus G., Schwabe H. K., Eichelbaum M. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klinische Wochenschrift 1985; 63: 1205–1211
- Moro E., Bellotti V., Marrari P., Pianezzola E., Stocco S., Valzelli G. Assay of LM 427 (Rifabutin) and its metabolites by h.p.l.c. in human plasma and urine. Abstracts of the 10th International Symposium on Column Liquid Chromatography. San Francisco 1986; 2740, 18-23 May
- Nakagawa H., Sunahara S. Rifampicin-glucuronide in human urine. Rifampicin, J. M. Dickinson. Excerpta Medica, Amsterdam 1974; 90–94
- Olliaro P., Strolin Benedetti M., Fanfani A., Repetto M. Rifabutine: activité et pharmacocinétique, Congres International de Pneumologie. Algiers. 1989, 4-7 June
- Park B. K., Breckenridge A.-M. Clinical implications of enzyme induction and enzyme inhibition. Clinical Pharmacokinetics 1981; 6: 1–24
- Rowland M., Tozer T. In Clinical Pharmacokinetics: Concepts and Applications, M. Rowland, T. Tozer. Lea and Febiger, Philadelphia 1989; 180–182
- Skinner M. H., Hsieh M., Torseth J., Pauloin D., Bhatia G., Harkonen S., Merigan T. C., Blaschke T. F. Pharmacokinetics of rifabutin. Antimicrobial Agents and Chemotherapy 1989; 33: 1237–1241
- Tomson T., Svensson J. O., Hilton-Brown P. Relationship of intraindividual dose to plasma concentration of carbamazepine: indication of dose-dependent induction of metabolism. Therapeutic Drug Monitoring 1989; 11: 533–539
- Ungheri D., Della Bruna C., Sanfilippo A. Activity of the spiropiperidyl rifamycin LM 427 on rifampicin resistant Mycobacterium tuberculosis. Giornale Italiano di Chemioterapia 1984; 31: 211–214
- Ungheri D., Franceschi G., Della Bruna C. Main human urinary metabolites of the spiropiperidyl rifamycin LM 427: isolation and biological properties. Proceedings of the 14th International Congress of Chemotherapy, J. Ishigami. University of Tokyo Press, Tokyo 1985; Vol. 3: 1917–1918
- Uncheri D., Penati V., Giobbi A. Rifabutin (LM 427): in vitro and in vivo activity against rifampicin-resistant and atypical mycobacteria. Proceedings of the International Symposium on Mycobacteria of Clinical Interest, M. Casal. Elsevier, Amsterdam 1986; 184–187
- Wagner J. G. In Fundamentals of Clinical Pharmacokinetics, J. G. Wagner. Drug Intelligence Publications, Inc., Hamilton, IL 1975; 138–139
- Winsel K., Iwainsky H., Werner E., Eule H. Trennung, Bestimmung und Pharmakoki-netik von Rifampicin und seinen Biotransformationsprodukten. Pharmazie 1976; 31: 95–99